Business
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the
About this update from Abivax Sa
[{"type":"image","alt":"Abivax","displaySize":"","headline":null,"caption":"Abivax","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v57CPS2C3Q2FJGKeA0P43g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73","width":300,"height":44}},"lazy":false},{"type":"text","content":"Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review","length":84,"tagName":"p"},{"type":"text","content":"PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices.","length":565,"tagName":"p"},{"type":"text","content":"This decision will take effect on Friday, September 19, 2025, after market close.","length":81,"tagName":"p"},{"type":"text","content":"The CAC Mid 60 and SBF 120 are key indices on the Euronext Paris exchange, representing mid-sized listed companies and a broader selection of 120 major securities, respectively. Inclusion in these indices enhances Abivax’s visibility and is expected to broaden the Company’s investor base by making its shares more accessible to institutional investors and index-linked funds.","length":376,"tagName":"p"},{"type":"text","content":""We are honored to be added to the Euronext CAC Mid 60 and SBF 120 indices," said Marc de Garidel, Chief Executive Officer of Abivax. "This recognition is a powerful testament to the financial markets' continued confidence in our strategic visions and our ability to execute them. This milestone also further validates our commitment to advancing innovative therapies for patients with chronic inflammatory diseases while driving long-term value for our shareholders."","length":492,"tagName":"p"},{"type":"text","co...